SavedAdd your journal

Journals / Tüberküloz ve Toraks / 2019 / Cilt: 67 - Sayı: 4

Eosinophilic asthma with chronic rhinosinusitis/nasal polyps and biologic agents

Kronik sinüzit/nazal polipli eozinofilik astım ve biyolojikler

İnsu YILMAZ
Pages
292–299
Publication Date
2022-11-04
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

In the present review,biological agents in eosinophilic asthma with CRSwNP will be discussed.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:he current understanding in severe asthma management is the targeted therapy approach with the evaluation of phenotypes and biomarkers.
📊
Key Findings & Data:Biological agentswhich specifically target type 2 (T2) high inflammation have been used in thissevere asthma phenotype with a preferable safety profile.
💡
Conclusion & Impact:In the present review,biological agents in eosinophilic asthma with CRSwNP will be discussed.
🔬Design:Review & Systematic Survey
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

he current understanding in severe asthma management is the targeted therapy approach with the evaluation of phenotypes and biomarkers. Therefore,personalized treatments are recently more prominent. Eosinophilic asthma withchronic rhinosinusitis/nasal polyps (CRSwNP) is one of the severe asthma phenotypes which needs a personalized treatment approach. Biological agentswhich specifically target type 2 (T2) high inflammation have been used in thissevere asthma phenotype with a preferable safety profile. In the present review,biological agents in eosinophilic asthma with CRSwNP will be discussed.

Özet

Ağır astımda hastalık yönetimi için yeni anlayış fenotip ve biyolojik belirteçlerin kullanılarak hedefe yönelik tedavilerin kullanılmasıdır. Bu nedenle günümüzde kişiselleştirilmiş tedaviler ön plana çıkmaktadır. Kronik rinosinüzit/ nazal polipli (CRSwNP) eozinofilik astım da kişiselleştirilmiş tedavi gerektiren ağır astım fenotiplerinden birisidir. Bu ağır astım fenotipinde tip 2 (T2) high inflamasyonu spesifik bir şekilde hedefleyen ve güvenlik profilleri çok iyi olan biyolojik ajanlar kullanılmaya başlanmıştır. Bu derlemede CRSwNP’li ağır eozinofilik astımda kullanılma potansiyeli olan biyolojik tedaviler ele alınacaktır.

🔖

Cite This Article

YILMAZ, İ. (2022). Eosinophilic asthma with chronic rhinosinusitis/nasal polyps and biologic agents. Tüberküloz ve Toraks, Cilt: 67 - Sayı: 4, 292–299. https://ajindex.com/articles/618398

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (14)

  1. Diffucult-to-treat and severe asthma in adolescent and adult patients Diagnosis and Management. GINA 2019. www.ginaasthma.org
  2. Asthma management and prevention for adults and children older than 5 years. GINA updated 2019. www. ginaasthma.org
  3. Fokkens WJ, Lund V, Bachert C, Mullol J, Bjermer L, Bousquet J, et al. EUFOREA consensus on biologics for CRSwNP with or without asthma. Allergy 2019;74(12):2312-9
  4. Lin DC, Chandra RK, Tan BK, Zirkle W, Conley DB, Grammer LC, et al. Association between severity of asthma and degree of chronic rhinosinusitis. Am J Rhinol Allergy 2011;25(4):205‐8
  5. Shaw DE, Sousa AR, Fowler SJ, Fleming LJ, Roberts G, Corfield J, et al. Clinical and inflammatory characteristics of the European U‐BIOPRED adult severe asthma cohort. Eur Respir J 2015;46(5):1308‐21
  6. Tomassen P, Vandeplas G, Van Zele T, Cardell LO, Arebro J, Olze H, et al. Inflammatory endotypes of chronic rhinosinusitis based on cluster analysis of biomarkers. J Allergy Clin Immunol 2016;137(5):1449-56
  7. Meltzer EO, Hamilos DL. Rhinosinusitis diagnosis and management for the clinician: a synopsis of recent consensus guidelines. Mayo Clin Proc 2011;86(5):427-43
  8. Fokkens WJ, Lund VJ, Mullol J, Bachert C, Alobid I, Baroody F, et al. EPOS 2012; European position paper on rhinosinusitis and nasal polyps. A summary for otorhinolaryngologists. Rhinology 2012;50(1):1-12
  9. Zervas E, Samitas K, Papaioannou AI, Bakakos P, Loukides S, Gaga M. An algorithmic approach for the treatment of severe uncontrolled asthma. ERJ Open Res 2018;4(1):00125-2017
  10. Wan XC, Woodruff PG. Biomarkers in severe asthma. Immunol Allergy Clin North Am 2016;36:547-57
  11. Chung KF, Wenzel SE, Brozek JL, Bush A, Castro M, Sterk PJ, et al. International ERS/ATS guidelines on definition, evaluation and treatment of severe asthma. Eur Respir J 2014;43:343-73
  12. Ortega H, Katz L, Gunsoy N, Keene O, Yancey S. Blood eosinophil counts predict treatment response in patients with severe eosinophilic asthma. J Allergy Clin Immunol 2015;136:825-6
  13. Simpson JL, Scott R, Boyle MJ, Gibson PG. Inflammatory subtypes in asthma: assessment and identification using induced sputum. Respirology 2006;11(1):54-61. 14. de Groot JC, Storm H, Amelink M, de Nijs SB, Eichhorn E, Reitsma BH, et al. Clinical profile of patients with adult-onset eosinophilic asthma. ERJ Open Res 2016;2(2):00100- 2015
  14. Belda J, Leigh R, Parameswaran K, O’Byrne PM, Sears MR, Hargreave FE. Induced sputum cell counts in healt